4
Tetrahedron
O
O
NH2
OH
O2N
N
N
65c
O
N
14
3o
2o
NO2
aAll the reactions were performed on 1 mmol scale with 1 equiv. of NaHCO3 in 5 ml ethanol at 60°C.
bPrecipitated yields.
cReaction performed in 1,4-dioxane under reflux condition
The structure of the product was confirmed by X-ray analysis
Acknowledgments
of 3d as shown in Figure 1. The molecule was crystallized in
monoclinic system with space group C 2/c with eight molecules
in the unit cell. The crystal is stabilized by C−H···O–, C−H···O
and C−H···Cl interactions. The chloro benzene ring is tilted by
12.8° away from the plane of the pyrimidine-N-oxide moiety
(Also refer crystal data and crystal packing diagram in
supplementary data).
We thank the Managing Trustee and the Chairman (Medical
Sciences), Sankar Foundation for their kind support.
Supplementary data
General experimental section, analytical data for compounds
3a-o and the X-ray analysis of 3d can be found in supplementary
data. Crystallographic data of 3d has been deposited with the
Cambridge Crystallographic Data Centre as supplementary
publication nos. CCDC 902947. The data can be obtained free of
Cambridge Crystallographic Data Centre (CCDC), 12 Union
Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033;
References and notes
1. (a) Bruno, O.; Schenone, S.; Ranise, A.; Bondavalli, F.; Barocelli,
E.; Ballabeni, V.; Chiavarini, M.; Bertoni, S.; Tognolini, M.;
Impicciatore, M. Bioorg. Med. Chem. 2001, 9, 629–636; (b)
Bruno, O.; Brullo, C.; Schenone, S.; Ranise, A.; Bondavalli, F.;
Barocelli, E.; Tognolini, M.; Magnanini, F.; Ballabeni, V.
Farmaco. 2002, 57, 753–758; (c) Bruno, O.; Brullo, C.; Schenone,
S.; Bondavalli, F.; Ranise, A.; Tognolini, M.; Ballabeni, V.;
Barocelli, E. Bioorg. Med. Chem. 2004, 12, 553–61; (d) Bruno,
O.; Brullo, C.; Bondavalli, F.; Ranise, A.; Schenone, S.;
Tognolini, M.; Ballabeni, V.; Barocelli, E. Med. Chem. 2007, 3,
127–34; (e) Keche, A. P.; Hatnapure, G. D.; Tale, R. H.; Rodge,
A. H.; Birajdar, S. S.; Kamble, V. M. Bioorg Med Chem Lett.
2012, 22, 3445-3448; (f) Ji Hoon, L.; Hyum-suk, L. Org. Biomol.
Chem. 2012, 10, 4229-4235.
Fig. 1. ORTEP plot for the X-ray crystal structure of 3d at 30% probability.
In all the above reactions (Table 2, entries 1-14) a precipitate
was observed after initial 15 minutes of reaction which re-
dissolves and re-precipitates to afford products 3a-o. The first
precipitated solid was isolated in the reaction of 2a with 1 and
confirmed as N-alkylated intermediate A of primary amine
(Scheme 1). Based on the above observations, mechanism as
shown in Scheme 1 can be proposed where the initial nucleophlic
addition of the primary amine on 1 leads to an N-alkylated
Intermediate A. Intermediate A further undergoes a base
catalyzed deprotonation triggering the nucleophilic addition of
the oxime amine on the aldehyde resulting in intermediate B,
which subsequently undergoes dehydration leading to the final
chromeno-pyrimidine-N-oxide 3a.
2. Messenger, A. G.; Rundegren, J. Br. J. Dermatol. 2004, 150, 186-
194 and references cited therein.
3. (a) Johnson, G. A.; Barsuhn, K. J.; McCall, J. M. Biochem.
Pharmacol. 1982, 31, 2949; (b) Meisheri, K. D.; Cipkus, L. A.;
Taylor, C. J. J. Pharmacol. Exp. Ther. 1988, 245, 751; (c)
Winquist, R. J.; Heaney, L. A.; Wallace, A. A.; Baskin, E. P.;
Stein, R. B.; Garcia, M. L.; Kaczorowsk, G. J. J. Pharmacol. Exp.
Ther. 1989, 248, 149; (d) Meisheri, K. D.; Johnson, G. A.;
Puddington, L. Biochem. Pharmacol. 1993, 45, 271; (e)
Anderson, R. J.; Kudlacek, P. E.; Clemens, D. L. Chem. Biol.
Interact. 1998, 109, 53.
O
N
O
N
O
O
O
N
O
O
N
O
N
OH
O
O
CHO
+H+
-H2O
+NaHCO3
-HCl
H
Cl
H
:N
1
O
O
H
NH2
Base
N
OH
4. Tseng, C. P. U.S. Patent 4,411,690, Oct 24, 1983. Chem. Abstr.
1984, 100, 34561.
3a
B
2a
A
5. Yamanaka, H.; Sakamoto, T.; Niitsuma, S. Heterocycles. 1990,
Scheme 1. Mechanism for the formation of 3a intermediate A.
31, 923–967.
In summary, we have reported a facile protocol for direct
access to novel chromeno-pyrimidine-N-oxides via tandem
double nucleophilic addition and dehydration steps. The reaction
offers a complementary approach for obtaining selective mono-
N-oxides products of pyrimidines in good yields. Additionally,
all the products were afforded as pure precipitates avoiding the
necessity for tedious column purification steps. Further
investigations on structural diversification and biological
implications of the structural scaffolds are currently being
conducted.
6. (a) Jandali.; Shareef.; Low.; David, W. Ann. Plast. Surg. 2010, 65,
437-442. Chem. Abstract, 1992, 116, 135998.
7. (a) Rousseau, R. J.; Robins, R. K. J. Heterocycl. Chem. 1965, 2,
196; (b) Kim, K. M.; Chung, K. H.; Kim, J. N.; Ryu, E. K.
Synthesis. 1993, 283; (c) Cartwright, D.; Ferguson, J. R.;
Giannopouls, T.; Varvounis, G.; Wakefield, B. J. Tetrahedron.
1995, 51, 12791.
8. (a) Katritzky, A. R. Chemistry of heterocyclic N-oxides,
Academic Presee London, 1971; (b) Hiroshi, Y.; Shigeru, O,
Takao, S. Heterocycles. 1981, 16, 573-576; (c) Jovanovic, M. V.
Canadian Journal of Chemistry, 1984, 62, 1176; (d) Thomos, J. K.
J.Org. Chem. 1985, 49, 3073.